GLP-1 Pipeline Update: May 2025

As the GLP-1 pipeline continues to grow, Prime actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The table below displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer published announcements or communications or are estimated based on study completion dates and may change as more information becomes available.

Drug / Dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	CKD + Obesity or overweight	MASH	Alzheimer's disease
Manufacturer: AstraZeneca													
exenatide (Byetta, Bydureon Bcise) / SC	FDA-approved (Byetta *only* ages ≥ 10 years)												
Manufacturer: Eli Lilly													
dulaglutide (Trulicity) / SC	FDA-approved (ages ≥ 10 years)		FDA-approved										
tirzepatide (Mounjaro) / SC	FDA-approved												
tirzepatide (Zepbound) / SC		FDA-approved						FDA-approved		FDA submission withdrawn	2027		
orforglipron / oral	2027	2026						2027					
retatrutide / SC	2027	2027		2027		2027		2027	2027				
Manufacturer: Novo Nordisk													
liraglutide (Victoza)* / SC	FDA-approved (ages ≥ 10 years)		FDA-approved										
liraglutide (Saxenda) / SC		FDA-approved (ages ≥ 12 years)											
liraglutide-insulin degludec (Xultophy) / SC	FDA-approved												
semaglutide (Rybelsus) 1.5–14 mg / oral	FDA-approved		FDA decision Oct. 2025										2027

Drug / Dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	CKD + Obesity or overweight	MASH	Alzheimer's disease
Manufacturer: Novo Nordisk (continued)													
semaglutide 25 mg (Wegovy) / oral		FDA decision 4Q2025		FDA decision 4Q2025									
semaglutide 25 mg, 50 mg (NN9924) /oral	2026												
semaglutide 1 mg, 2 mg (Ozempic) / SC	FDA-approved		FDA-approved		FDA decision 2025	FDA-approved	2027						
semaglutide 1.7 mg, 2.4 mg (Wegovy) / SC		FDA-approved (ages ≥ 12 years)		FDA-approved					2026	FDA decision 4Q2025		2.4 mg FDA decision 3Q2025	
semaglutide + insulin icodec / SC	2026												
cagrilintide + semaglutide / SC	2027	2027											
Manufacturer: Sanofi													
lixisenatide + insulin glargine (Soliqua) / SC	FDA-approved												
Manufacturer: Zealand, Boehringer Ingelheim													
survodutide / SC												2027	

*generics available

Glossary

CKD Chronic kidney disease
CVD Cardiovascular disease
FDA Food and Drug Administration
GLP-1 Glucagon-like peptide-1 receptor agonist
HF Heart failure
MASH Metabolic dysfunction-associated steatohepatitis
OA Osteoarthritis
OSA Obstructive sleep apnea
PAD Peripheral arterial disease
SC Subcutaneous
T2DM Type 2 diabetes mellitus

Disclaimer